Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, Maddukuri G, Tsai CY, Floyd T, Al-Aly Z. Analysis of the global burden of disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int. 2018;94(3):567–81.
Article
Google Scholar
Gheith O, Farouk N, Nampoory N, Halim MA, Al-Otaibi T. Diabetic kidney disease: world wide difference of prevalence and risk factors. J Nephropharmacol. 2016;5(1):49–56.
PubMed
Google Scholar
Bailey RA, Wang Y, Zhu V, Rupnow MF. Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on kidney disease: improving global outcomes (KDIGO) staging. BMC Res Notes. 2014;7:415.
Article
Google Scholar
Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032–45.
Article
CAS
Google Scholar
Narres M, Claessen H, Droste S, Kvitkina T, Koch M, Kuss O, Icks A. The incidence of end-stage renal disease in the diabetic (compared to the non-diabetic) population: a systematic review. PLoS ONE. 2016;11(1):e0147329.
Article
Google Scholar
Nichols GA, Deruaz-Luyet A, Hauske SJ, Brodovicz KG. The association between estimated glomerular filtration rate, albuminuria, and risk of cardiovascular hospitalizations and all-cause mortality among patients with type 2 diabetes. J Diabetes Complicat. 2018;32(3):291–7.
Article
Google Scholar
Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14(6):361–77.
Article
CAS
Google Scholar
Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81.
Article
CAS
Google Scholar
de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305(24):2532–9.
Article
Google Scholar
Kosiborod M, Gomes MB, Nicolucci A, Pocock S, Rathmann W, Shestakova MV, Watada H, Shimomura I, Chen H, Cid-Ruzafa J, Fenici P, Hammar N, Surmont F, Tang F, Khunti K, Investigators D. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program). Cardiovasc Diabetol. 2018;17(1):150.
Article
Google Scholar
Wilke T, Ahrendt P, Schwartz D, Linder R, Ahrens S, Verheyen F. Incidence and prevalence of type 2 diabetes mellitus in Germany: an analysis based on 5.43 million patients. Dtsch Med Wochenschr. 2013;138(3):69–75.
Article
CAS
Google Scholar
Schipf S, Werner A, Tamayo T, Holle R, Schunk M, Maier W, Meisinger C, Thorand B, Berger K, Mueller G, Moebus S, Bokhof B, Kluttig A, Greiser KH, Neuhauser H, Ellert U, Icks A, Rathmann W, Volzke H. Regional differences in the prevalence of known Type 2 diabetes mellitus in 45-74 years old individuals: results from six population-based studies in Germany (DIAB-CORE Consortium). Diabet Med. 2012;29(7):e88–95.
Article
CAS
Google Scholar
Muller N, Heller T, Freitag MH, Gerste B, Haupt CM, Wolf G, Muller UA. Healthcare utilization of people with type 2 diabetes in Germany: an analysis based on health insurance data. Diabet Med. 2015;32(7):951–7.
Article
CAS
Google Scholar
Waldeyer R, Brinks R, Rathmann W, Giani G, Icks A. Projection of the burden of type 2 diabetes mellitus in Germany: a demographic modelling approach to estimate the direct medical excess costs from 2010 to 2040. Diabet Med. 2013;30(8):999–1008.
Article
CAS
Google Scholar
Du Y, Heidemann C, Schaffrath Rosario A, Buttery A, Paprott R, Neuhauser H, Riedel T, Icks A, Scheidt-Nave C. Changes in diabetes care indicators: findings from German national health interview and examination surveys 1997–1999 and 2008–2011. BMJ Open Diabetes Res Care. 2015;3(1):e000135.
Article
Google Scholar
Danne T, Kaltheuner M, Koch A, Ernst S, Rathmann W, Russmann HJ, Bramlage P, Studiengruppe D. “DIabetes Versorgungs-Evaluation” (DIVE)—a national quality assurance initiative at physicians providing care for patients with diabetes. Dtsch Med Wochenschr. 2013;138(18):934–9.
Article
CAS
Google Scholar
Bramlage P, Bluhmki T, Rathmann W, Kaltheuner M, Beyersmann J, Danne T, Group DS. Identifying patients with type 2 diabetes in which basal supported oral therapy may not be the optimal treatment strategy. Diabetes Res Clin Pract. 2016;116:127–35.
Article
Google Scholar
Ulm University. Diabetes-Patienten-Verlaufsdokumentation (DPV) http://buster.zibmt.uni-ulm.de/dpv/index.php/en/. Accessed 7 Jan 2019.
Bohn B, Schofl C, Zimmer V, Hummel M, Heise N, Siegel E, Karges W, Riedl M, Holl RW. initiative DPV: achievement of treatment goals for secondary prevention of myocardial infarction or stroke in 29,325 patients with type 2 diabetes: a German/Austrian DPV-multicenter analysis. Cardiovasc Diabetol. 2016;15(1):72.
Article
Google Scholar
Schwab KO, Doerfer J, Hungele A, Scheuing N, Krebs A, Dost A, Rohrer TR, Hofer S, Holl RW. Non-high-density lipoprotein cholesterol in children with diabetes: proposed treatment recommendations based on glycemic control, body mass index, age, sex, and generally accepted cut points. J Pediatr. 2015;167(6):1436–9.
Article
Google Scholar
Danne T, Bluhmki T, Seufert J, Kaltheuner M, Rathmann W, Beyersmann J, Bramlage P, Group DS. Treatment intensification using long-acting insulin–predictors of future basal insulin supported oral therapy in the DIVE registry. BMC Endocr Disord. 2015;15:54.
Article
Google Scholar
Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. Kidney Int. 2011;80(1):17–28.
Article
Google Scholar
KDIGO 2012. Clinical practice guideline for the evaluation and management of chronic kidney disease: Chapter 1: definition and classification of CKD. Kidney Int Suppl. 2013;3:19–62.
Schwandt A, Denkinger M, Fasching P, Pfeifer M, Wagner C, Weiland J, Zeyfang A, Holl RW. Comparison of MDRD, CKD-EPI, and Cockcroft–Gault equation in relation to measured glomerular filtration rate among a large cohort with diabetes. J Diabetes Complicat. 2017;31(9):1376–83.
Article
Google Scholar
Ozieh MN, Dismuke CE, Lynch CP, Egede LE. Medical care expenditures associated with chronic kidney disease in adults with diabetes: United States 2011. Diabetes Res Clin Pract. 2015;109(1):185–90.
Article
Google Scholar
Vupputuri S, Kimes TM, Calloway MO, Christian JB, Bruhn D, Martin AA, Nichols GA. The economic burden of progressive chronic kidney disease among patients with type 2 diabetes. J Diabetes Complicat. 2014;28(1):10–6.
Article
Google Scholar
Muller G, Kluttig A, Greiser KH, Moebus S, Slomiany U, Schipf S, Volzke H, Maier W, Meisinger C, Tamayo T, Rathmann W, Berger K. Regional and neighborhood disparities in the odds of type 2 diabetes: results from 5 population-based studies in Germany (DIAB-CORE consortium). Am J Epidemiol. 2013;178(2):221–30.
Article
Google Scholar
Girndt M, Trocchi P, Scheidt-Nave C, Markau S, Stang A. The prevalence of renal failure. Results from the German health interview and examination survey for adults, 2008–2011 (DEGS1). Dtsch Arztebl Int. 2016;113(6):85–91.
PubMed
PubMed Central
Google Scholar
Titze S, Schmid M, Kottgen A, Busch M, Floege J, Wanner C, Kronenberg F, Eckardt KU, Investigators GS. Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German chronic kidney disease (GCKD) cohort. Nephrol Dial Transplant. 2015;30(3):441–51.
Article
Google Scholar
Velho G, Ragot S, El Boustany R, Saulnier PJ, Fraty M, Mohammedi K, Fumeron F, Potier L, Marre M, Hadjadj S, Roussel R. Plasma copeptin, kidney disease, and risk for cardiovascular morbidity and mortality in two cohorts of type 2 diabetes. Cardiovasc Diabetol. 2018;17(1):110.
Article
Google Scholar
Zobel EH, von Scholten BJ, Reinhard H, Persson F, Teerlink T, Hansen TW, Parving HH, Jacobsen PK, Rossing P. Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria. Cardiovasc Diabetol. 2017;16(1):88.
Article
Google Scholar
Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: UK prospective diabetes study 74. Diabetes. 2006;55(6):1832–9.
Article
CAS
Google Scholar
Owusu Adjah ES, Bellary S, Hanif W, Patel K, Khunti K, Paul SK. Prevalence and incidence of complications at diagnosis of T2DM and during follow-up by BMI and ethnicity: a matched case–control analysis. Cardiovasc Diabetol. 2018;17(1):70.
Article
Google Scholar
Low S, Zhang X, Wang J, Yeoh LY, Liu YL, Ang SF, Subramaniam T, Sum CF, Lim SC. The impact of HbA1c trajectories on chronic kidney disease progression in type 2 diabetes. Nephrology (Carlton). 2018. https://doi.org/10.1111/nep.13533.
Article
Google Scholar
Busch M, Nadal J, Schmid M, Paul K, Titze S, Hubner S, Kottgen A, Schultheiss UT, Baid-Agrawal S, Lorenzen J, Schlieper G, Sommerer C, Krane V, Hilge R, Kielstein JT, Kronenberg F, Wanner C, Eckardt KU, Wolf G, Investigators GS. Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease—cross-sectional data from the German chronic kidney disease (GCKD) cohort. BMC Nephrol. 2016;17(1):59.
Article
Google Scholar
Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM. Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study. Arch Intern Med. 2003;163(13):1555–65.
Article
Google Scholar
Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ. Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations. J Am Soc Nephrol. 2005;16(10):3027–37.
Article
CAS
Google Scholar
Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME. Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care. 2014;37(10):2864–83.
Article
Google Scholar
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–9.
Article
CAS
Google Scholar
Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892–903.
Article
CAS
Google Scholar
Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsarinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372(9638):547–53.
Article
CAS
Google Scholar
Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005;28(9):2106–12.
Article
CAS
Google Scholar
Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1(5):940–51.
Article
CAS
Google Scholar
Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014. https://doi.org/10.1002/14651858.CD007004.pub3.
Article
PubMed
Google Scholar
Athyros VG, Doumas M, Imprialos KP, Stavropoulos K, Georgianou E, Katsimardou A, Karagiannis A. Diabetes and lipid metabolism. Hormones (Athens). 2018;17(1):61–7.
Article
Google Scholar
Sacks FM, Hermans MP, Fioretto P, Valensi P, Davis T, Horton E, Wanner C, Al-Rubeaan K, Aronson R, Barzon I, Bishop L, Bonora E, Bunnag P, Chuang LM, Deerochanawong C, Goldenberg R, Harshfield B, Hernandez C, Herzlinger-Botein S, Itoh H, Jia W, Jiang YD, Kadowaki T, Laranjo N, Leiter L, Miwa T, Odawara M, Ohashi K, Ohno A, Pan C, Pan J, Pedro-Botet J, Reiner Z, Rotella CM, Simo R, Tanaka M, Tedeschi-Reiner E, Twum-Barima D, Zoppini G, Carey VJ. Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus: a global case–control study in 13 countries. Circulation. 2014;129(9):999–1008.
Article
CAS
Google Scholar
Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–88.
Article
CAS
Google Scholar
Palsson R, Patel UD. Cardiovascular complications of diabetic kidney disease. Adv Chronic Kidney Dis. 2014;21(3):273–80.
Article
Google Scholar
Afkarian M, Sachs MC, Kestenbaum B, Hirsch IB, Tuttle KR, Himmelfarb J, de Boer IH. Kidney disease and increased mortality risk in type 2 diabetes. J Am Soc Nephrol. 2013;24(2):302–8.
Article
CAS
Google Scholar
Maier W, Holle R, Hunger M, Peters A, Meisinger C, Greiser KH, Kluttig A, Volzke H, Schipf S, Moebus S, Bokhof B, Berger K, Mueller G, Rathmann W, Tamayo T, Mielck A. The impact of regional deprivation and individual socio-economic status on the prevalence of Type 2 diabetes in Germany. A pooled analysis of five population-based studies. Diabet Med. 2013;30(3):e78–86.
Article
CAS
Google Scholar
Mathur R, Dreyer G, Yaqoob MM, Hull SA. Ethnic differences in the progression of chronic kidney disease and risk of death in a UK diabetic population: an observational cohort study. BMJ Open. 2018;8(3):e020145.
Article
Google Scholar